Steve, Hambrecht, Monty and Suntrust are decent underwriters. I just review some of the reports on ACDO from Goldman and BEST; the year to year topline and bottomline growth are impressive, 57% and 151% respectively, but can't find any sizzle in this company as yet.
Some brief info on ACDO: Accredo Health, Incorporated
1640 Century Center Pkwy.,
Ste. 101
Memphis, TN 38134
Phone: 901-385-3688
Fax: 901-385-3776
Web Site: accredohealth.com
IPO
INFORMATION
Filing date: September 1, 1998
Expected IPO date: TBA
Exchange: Nasdaq
Proposed ticker: ACDO
Offering amount (mil.): $74.8
Underwriters:
Hambrecht & Quist; NationsBanc
Montgomery Securities LLC; Suntrust
Equitable Securities
KEY NUMBERS
Fiscal Year-End: June
1998 Sales (mil.): $181.0
1-Yr. Sales Change: 57.1%
1998 Income (mil.): $2.8
1-Yr. Income Change: 151.4%
Employees: 271
More Financials
KEY PEOPLE
CEO: David D. Stevens
CFO: Joel R. Kimbrough
HR: Jill Stem
When a spoonful of sugar won't help the medicine go down,
perhaps Accredo Health can help. Formerly known as Nova
Factor, the company provides pharmacy and treatment
program management for Gaucher's disease (a liver
condition), hemophilia, multiple sclerosis, and Crohn's
disease (an intestinal inflammation). Accredo delivers
medications, assists with treatment programs, and provides
payment claims processing services. But it is not a
disinterested bystander. Most of its medications are made by
single manufacturers (including Genzyme, Biogen, and
Centocor) for which it provides consulting on pricing,
packaging, and marketing. The company also seeks
relationships with care providers (mostly in Texas) and
payers.
|
